On September 14, 2026, Nasus Pharma Ltd. announced that the U.S. Food and Drug Administration cleared its Investigational New Drug application for NS002, an investigational intranasal epinephrine powder designed as a needle-free alternative to EpiPen for treating anaphylaxis. The company plans to initiate a pivotal clinical study in the fourth quarter of 2026, with top-line data readout anticipated in the first quarter of 2027. This regulatory milestone advances NS002 toward commercialization in a market currently dominated by injectable autoinjectors. Nasus Pharma Ltd. is a biopharmaceutical company advancing innovative intranasal therapies through its proprietary powder technology platform.
